| Polyphenol and tannin nutraceuticals and their metabolites: How the human gut microbiota influences their properties M Fabbrini, F D’Amico, M Barone, G Conti, M Mengoli, P Brigidi, S Turroni Biomolecules 12 (7), 875, 2022 | 39 | 2022 |
| Pharmacomicrobiomics in anticancer therapies: why the gut microbiota should be pointed out G Conti, F D’Amico, M Fabbrini, P Brigidi, M Barone, S Turroni Genes 14 (1), 55, 2022 | 15 | 2022 |
| Gut microbiota resilience and recovery after anticancer chemotherapy S Roggiani, M Mengoli, G Conti, M Fabbrini, P Brigidi, M Barone, ... Microbiome Research Reports 2 (3), 2023 | 10 | 2023 |
| Bifidobacterium in anticancer immunochemotherapy: friend or foe? G Procaccianti, S Roggiani, G Conti, P Brigidi, S Turroni, F D’Amico Microbiome Research Reports 2 (3), 2023 | 9 | 2023 |
| A comparative absorption study of sucrosomial® orodispersible vitamin D3 supplementation vs. a reference chewable tablet and soft gel capsule vitamin D3 in … A Bano, S Abrar, E Brilli, G Tarantino, AA Bugti, M Fabbrini, G Conti, ... Frontiers in Nutrition 10, 1221685, 2023 | 5 | 2023 |
| Microbiota-gut-brain axis and ketogenic diet: how close are we to tackling epilepsy? M Mengoli, G Conti, M Fabbrini, M Candela, P Brigidi, S Turroni, ... Microbiome Research Reports 2 (4), 2023 | 4 | 2023 |
| The gut microbiota as an early predictor of COVID-19 severity M Fabbrini, F D’Amico, BTF van der Gun, M Barone, G Conti, S Roggiani, ... Msphere 9 (10), e00181-24, 2024 | 1 | 2024 |
| Interplay between WNT/PI3K-mTOR axis and the microbiota in APC-driven colorectal carcinogenesis: data from a pilot study and possible implications for CRC prevention FJ Di Paola, C Alquati, G Conti, G Calafato, S Turroni, F D’Amico, ... Journal of translational medicine 22 (1), 631, 2024 | 1 | 2024 |
| Gut Microbiome as a Potential Marker of Hematologic Recovery Following Induction Therapy in Acute Myeloid Leukemia Patients V Salvestrini, G Conti, F D'Amico, G Cristiano, M Candela, M Cavo, ... Cancer Medicine 14 (3), e70501, 2025 | | 2025 |
| Comparative bioavailability study of supplemental oral Sucrosomial® vs. oral conventional vitamin B12 in enhancing circulatory B12 levels in healthy deficient … NM Memon, G Conti, E Brilli, G Tarantino, MNA Chaudhry, A Baloch, ... Frontiers in Nutrition 11, 1493593, 2024 | | 2024 |
| Role of gut microbiome in the outcome of lymphoma patients treated with checkpoint inhibitors—The MicroLinf Study B Casadei, G Conti, M Barone, S Turroni, S Guadagnuolo, A Broccoli, ... Hematological Oncology 42 (5), e3301, 2024 | | 2024 |
| Early and late gut microbiota signatures of stroke in high salt-fed stroke-prone spontaneously hypertensive rats S Bencivenni, S Roggiani, A Zannoni, G Conti, M Fabbrini, M Cotugno, ... Scientific Reports 14 (1), 19575, 2024 | | 2024 |
| Interaction between gut microbiome and immune checkpoint inhibitor treatment in lymphoma patients: Final results of the MICRO‐LINF study. B Casadei, L Argnani, S Guadagnuolo, L Nanni, C Pellegrini, A Broccoli, ... Hematological Oncology 41, 2023 | | 2023 |
| Gut microbiome in DLBCL patients undergoing first‐line R‐CHOP regimen—The Oncopassport Study. V Stefoni, L Argnani, B Casadei, G Musuraca, L Nanni, C Pellegrini, ... Hematological Oncology 41, 2023 | | 2023 |
| Design of New Personalized Therapeutic Approaches for Diffuse Large B-Cell Lymphoma through Gut Microbiome Profiling L Nanni, G Musuraca, A Morigi, V Stefoni, M Barone, G Conti, M Fabbrini, ... Blood 140 (Supplement 1), 4961-4963, 2022 | | 2022 |
